From peptide 2° structures to small molecule inhibitors: the Edelris Discovery ENgine (EDEN)

webinar

Wed, 04 Nov 2015, 16:00 CET (Berlin)

Dr. Didier Roche, Edelris France

From peptide 2° structures to small molecule inhibitors: the Edelris Discovery ENgine (EDEN)

Edelris has pioneered for the past decade the design and synthesis of innovative, natural product-like small molecules (Keymical CollectionsTM) and generated its own Keymical SpaceTM representing over 8 M cpds. The EDEN platform (Edelris Discovery ENgine) has been developed to combine the leading role of structural information in drug discovery with the attractiveness of our Keymical SpaceTM in order to design compounds exploring new boundaries in the modulation of biological systems and particularly to address PPIs.

We will present in this webinar the approach used to design compounds mimicking alpha helix peptide secondary structures. 3D-Pharmacophore data mining using ReCore proved to be successful to discover original and drug-like modulators of the MDM2/P53 interaction.

Current news

VAST Just Got Bigger — The September 2026 Update
September 17, 2026 09:00 CEST
More compounds. More chemistry. More opportunities to discover your next active. This August, explore Enamine’s largest compound catalog with infiniSee xREAL as BioSolveIT’s Tool of the Month. XtalPi has expanded its VAST Chemical Space, giving you access to almost six billion virtual product molecules built from over 25,000 carefully selected...
Read on
category
Events
Boston Event: Expanding Molecular Diversity with CORE
September 15, 2026 17:27 CEST
Chemical Space Exploration Meets AI in Boston BioSolveIT and Onepot.AI invite you to an evening of science, drinks, and conversation at D16, the speakeasy beneath Dillon’s in Boston. Join us on September 30, 2026, for two very concise presentations exploring how ultra-large Chemical Spaces and artificial intelligence can open new...
Read on
category
Events
Beyond the Flatland: sp³-Rich Fragments Unlock Novel Kinase Chemotypes: Free Webinar!
September 15, 2026 10:40 CEST
Kinases are among the most intensively pursued target families in drug discovery, yet the chemical matter screened against them remains surprisingly narrow. Conventional kinase-focused libraries are dominated by flat, heteroaromatic compounds, while saturated, three-dimensional molecules stay largely underexplored. That narrow structural diversity makes it harder to find genuinely novel chemotypes,...
Read on